Emerging therapeutic uses of direct‐acting oral anticoagulants: An evidence‐based perspective

@article{Raschi2017EmergingTU,
  title={Emerging therapeutic uses of direct‐acting oral anticoagulants: An evidence‐based perspective},
  author={Emanuel Raschi and Matteo Bianchin and Roberto De Ponti and Fabrizio De Ponti and Walter Ageno},
  journal={Pharmacological Research},
  year={2017},
  volume={120},
  pages={206–218}
}

Figures and Tables from this paper

Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?
TLDR
The latest evidence on the evolving therapeutic uses of direct-acting oral anticoagulant agents in the cardiovascular area is updated, addressing potential impact for clinicians.
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews
TLDR
The evidence gathered so far on the risk–benefit profile of direct oral anticoagulants is appraised in the light of existing guidelines to discuss whether further implementation should be proposed.
What are the Characteristics of Patients Experiencing Adverse Drug Reactions to Oral Anticogulants and How Can Such Reactions be Prevented?
TLDR
A large percentage of ADRs from oral anticoagulant use can be avoided with more careful patient management, and periodic check-up of cardiac and renal function, as well as blood count, may be useful for reducing the risk of ADR, especially in older DOACs users.
Drug–Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review
TLDR
Real-world studies are needed to assess the clinical relevance of the pharmacokinetic interactions with dabigatran and describe the actual spectrum of possible DDIs between DAAs and other DOACs.
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations
TLDR
Key challenges emerging from critical appraisal of the ESC position paper are discussed, including the wide spectrum of cardiovascular toxicities associated with oncological drugs, focusing on targeted agents, and the evolving role of anticoagulation in oncology.
Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome
TLDR
A case report is presented that illustrates there may be important dosing issues when considering the use of these agents in patients with the antiphospholipid syndrome.
Prognostic and therapeutic implications of vascular disease in patients with atrial fibrillation
Perceptions of patients and healthcare providers on patient education to improve oral anticoagulant management.
TLDR
The findings suggest that patients, caregivers and healthcare providers support the need for education on OACs, including for patients taking DOACs and specific important content and proper education format are needed.
The ups and downs of anticoagulation prescription in the United Kingdom
TLDR
Despite all these positive efforts, some aspects of anticoagulation therapy have been recently noted to represent problem areas, which will be discussed in this review.
...
...

References

SHOWING 1-10 OF 101 REFERENCES
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications.
TLDR
This critical review aimed to evaluate the evidence on the latest debated safety issues potentially associated with the use of non-vitamin K oral anticoagulants in the postmarketing setting and assesses the potential coronary risk, liver injury, and the potential for renal damage.
Meta‐analysis of the efficacy and safety of new oral anticoagulants in patients with cancer‐associated acute venous thromboembolism: comment
TLDR
The efficacy outcome was recurrent VTE, and the safety outcome was major and clinically relevant non-major bleeding, form a solid basis for the initiation of a head-to-head comparison of NOACs with LMWH in cancer patients.
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants.
TLDR
The pharmacology of the direct oral anticoagulants is reviewed and the advantages of the DOACs over vitamin K antagonists are described, as well as highlighting current challenges and limitations, and identifying future directions for antICOagulant therapy.
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population
TLDR
The two classes of DOACs and the drugs they are comprised of are factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitor (dabigatran) and off-label usage of these agents is largely based on adult doses.
Non-Vitamin K Antagonist Oral Anticoagulants and the Treatment of Venous Thromboembolism in Cancer Patients: A Semi Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes
TLDR
Point estimates of the effect size suggest an important estimated beneficial effect of NOAC in the treatment of VTE in cancer, in terms of efficacy and safety, but given the small numbers of patients with cancer in the randomised trials, statistical significance was not achieved.
Novel oral anticoagulants for heparin-induced thrombocytopenia
TLDR
Case reports have indicated positive results in patients, with clinical outcomes and tolerability supporting the use of the NOACs as alternative agents in the treatment of HIT, and further robust studies are needed for definitive decision making by clinicians.
Italian intersociety consensus on DOAC use in internal medicine
TLDR
This document formulates expert opinion guidance for pragmatic managing, monitoring and reversing the anticoagulant effect of DOACs in both chronic and emergency settings.
...
...